Detalles de la búsqueda
1.
Efficacy of niraparib by time of surgery and postoperative residual disease status: A post hoc analysis of patients in the PRIMA/ENGOT-OV26/GOG-3012 study.
Gynecol Oncol
; 166(1): 36-43, 2022 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-35550709
2.
Efficacy and safety of tisotumab vedotin in previously treated recurrent or metastatic cervical cancer (innovaTV 204/GOG-3023/ENGOT-cx6): a multicentre, open-label, single-arm, phase 2 study.
Lancet Oncol
; 22(5): 609-619, 2021 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-33845034
3.
Final analysis of the randomised PEAK trial: overall survival and tumour responses during first-line treatment with mFOLFOX6 plus either panitumumab or bevacizumab in patients with metastatic colorectal carcinoma.
Int J Colorectal Dis
; 32(8): 1179-1190, 2017 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-28424871
4.
TG4010 immunotherapy and first-line chemotherapy for advanced non-small-cell lung cancer (TIME): results from the phase 2b part of a randomised, double-blind, placebo-controlled, phase 2b/3 trial.
Lancet Oncol
; 17(2): 212-223, 2016 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-26727163
5.
BRCA1/2 mutations associated with progression-free survival in ovarian cancer patients in the AGO-OVAR 16 study.
Gynecol Oncol
; 140(3): 443-9, 2016 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-26740259
6.
Phase II study of weekly paclitaxel/carboplatin in combination with prophylactic G-CSF in the treatment of gynecologic cancers: A study in 108 patients by the Belgian Gynaecological Oncology Group.
Gynecol Oncol
; 138(2): 278-84, 2015 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-26049123
7.
Tisotumab Vedotin in Combination With Carboplatin, Pembrolizumab, or Bevacizumab in Recurrent or Metastatic Cervical Cancer: Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study.
J Clin Oncol
; 41(36): 5536-5549, 2023 Dec 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-37651655
8.
Elacestrant (oral selective estrogen receptor degrader) Versus Standard Endocrine Therapy for Estrogen Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From the Randomized Phase III EMERALD Trial.
J Clin Oncol
; 40(28): 3246-3256, 2022 10 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-35584336
9.
Patient-Reported Outcomes in Patients With PIK3CA-Mutated Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer From SOLAR-1.
J Clin Oncol
; 39(18): 2005-2015, 2021 06 20.
Artículo
en Inglés
| MEDLINE | ID: mdl-33780274
10.
Fortnightly or fractionated weekly docetaxel-cisplatin-5-FU as first-line treatment in advanced gastric and gastroesophageal junction adenocarcinoma: The randomized phase II DoGE study.
Cancer Med
; 10(13): 4366-4374, 2021 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-34057299
11.
Sapanisertib Plus Exemestane or Fulvestrant in Women with Hormone Receptor-Positive/HER2-Negative Advanced or Metastatic Breast Cancer.
Clin Cancer Res
; 27(12): 3329-3338, 2021 06 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-33820779
12.
Prognostic value of KRAS mutations in stage III colon cancer: post hoc analysis of the PETACC8 phase III trial dataset.
Ann Oncol
; 26(4): 822-825, 2015 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-25814651
13.
Correlation between hematological parameters and outcome in patients with locally advanced cervical cancer treated by concomitant chemoradiotherapy.
Cancer Med
; 9(22): 8432-8443, 2020 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-32954675
14.
Exploratory pooled analysis evaluating the effect of sequence of biological therapies on overall survival in patients with RAS wild-type metastatic colorectal carcinoma.
ESMO Open
; 3(2): e000297, 2018.
Artículo
en Inglés
| MEDLINE | ID: mdl-29531837
15.
Eltrombopag for thrombocytopenia in patients with advanced solid tumors receiving gemcitabine-based chemotherapy: a randomized, placebo-controlled phase 2 study.
Int J Hematol
; 106(6): 765-776, 2017 Dec.
Artículo
en Inglés
| MEDLINE | ID: mdl-28864871
16.
Eltrombopag with gemcitabine-based chemotherapy in patients with advanced solid tumors: a randomized phase I study.
Cancer Med
; 4(1): 16-26, 2015 Jan.
Artículo
en Inglés
| MEDLINE | ID: mdl-25165041
17.
Skin lesions in European hibernating bats associated with Geomyces destructans, the etiologic agent of white-nose syndrome.
PLoS One
; 8(9): e74105, 2013.
Artículo
en Inglés
| MEDLINE | ID: mdl-24023927
18.
Targeted MET inhibition in castration-resistant prostate cancer: a randomized phase II study and biomarker analysis with rilotumumab plus mitoxantrone and prednisone.
Clin Cancer Res
; 19(1): 215-24, 2013 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-23136195
19.
Nonadherence to imatinib treatment in patients with gastrointestinal stromal tumors: the ADAGIO study.
Anticancer Res
; 31(4): 1407-9, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21508393
20.
Pan-European distribution of white-nose syndrome fungus (Geomyces destructans) not associated with mass mortality.
PLoS One
; 6(4): e19167, 2011 Apr 27.
Artículo
en Inglés
| MEDLINE | ID: mdl-21556356
Resultados
1 -
20
de 20
1
Próxima >
>>